The Challenge of Subgroup Analyses — Reporting without Distorting
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Subgroup analyses are an important part of the analysis of a comparative clinical trial. However, they are commonly overinterpreted14 and can lead to further research that is misguided or, worse, to suboptimal patient care.Consider a randomized, clinical trial designed to determine whether a new treatment is more effective than an established treatment and assessed with a test, based on all randomized patients, of the null hypothesis that the treatments have equal efficacy, as measured in terms of the primary end point. Then, subgroup analyses are conducted to assess whether different types of patients respond differently to the new . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, analyses of HRQoL, IBS symptoms and stool characteristics data were performed in the subgroup of those definitely constipated subjects (n = 19), as defined on the only basis of <3 stools per week; a lower significance level (P < 0.001) was applied for judging results in this subgroup, as recommended.36”
Citations
Cites
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,837
Subgroup analysis and other (mis)uses of baseline data in clinical trials
Assmann, S. F., Pocock, S. J., Enos, L. E., & Kasten, L. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02039-0 · Cited by 1,167
Yusuf, S. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470010097038 · Cited by 1,014
Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction
Antman, E. M., Morrow, D. A., McCabe, C. H., Murphy, S. A., Ruda, M., Sadowski, Z., Budaj, A., López-Sendón, J. L., Guneri, S., Jiang, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060898 · Cited by 609
Cornell, R. G., Wolf, F. M., Bailar, J. C., & Mosteller, F. (1989) · Journal of the American Statistical Association · doi:10.2307/2289981 · Cited by 295
Yusuf, S. (1991) · JAMA · doi:10.1001/jama.266.1.93 · Cited by 129
Subgroups, treatment effects, and baseline risks: Some lessons from major cardiovascular trials
Parker, A. B., & Naylor, C. D. (2000) · American Heart Journal · doi:10.1067/mhj.2000.106610 · Cited by 61
Bailar, J. C. (1986) · Cited by 28
Cited by
Items 401–496 of 496
Subgroup Identification and Variable Selection from Randomized Clinical Trial Data.
Foster, J. C. (2013) · Deep Blue (University of Michigan) · Cited by 5
Estimating Individual Causal Effects
Lam, P. (2013) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 2
COMMIT/CCS-2 studies – Authors' reply
Chen, Z., Collins, R., & Peto, R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69236-2 · Cited by 2
Linefsky, J. P., Lin, M. J., Pieper, K. S., Reist, C. J., Berdan, L. G., Antman, E. M., Goodman, S. G., French, J. K., Güneri, S., Roe, M. T., et al. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.06.056 · Cited by 2
Uncovering Individualised Treatment Effect: Evidence from Educational TrialsPreprint
Xiao, Z., Hauser, O., Kirkwood, C., Li, D. Z., Jones, B., & Higgins, S. (2020) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/8nsw4 · Cited by 2
RACING to judgement: weighing the value of pre-specified subgroup analyses
Stone, N. J. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac782 · Cited by 2
Martínez-Puig, P., Gutiérrez, N. B., Ramallo, H. R., Martín, L. A., & Otero, R. (2025) · PLoS ONE · doi:10.1371/journal.pone.0318739 · Cited by 2
Scholte, N. T. B., Clephas, P. R. D., Boersma, E. H., Gürgöze, M. T., Ronner, E., Feyz, L., de Boer, R. A., van der Boon, R. M. A., & Brugts, J. J. (2026) · npj Digital Medicine · doi:10.1038/s41746-026-02415-w · Cited by 2
“Both unadjusted and adjusted p -values for interaction were presented 103 – 106 .”
Leveraging clinical epidemiology concepts to strengthen machine learning fairness evaluations
Guo, L. L., Arciniegas, S. E., Yan, A. P., TOMLINSON, G. A., Beauchemin, M., Pfohl, S. R., & Sung, L. (2026) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocag041 · Cited by 1
A shrinkage estimator for subgroup analysis without the exchangeability assumption
Snapinn, S. M. (2021) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2021.1998101 · Cited by 1
“…is an expectation of a consistent treatment effect across subgroups (e.g., Grouin et al. 2005), and at the analysis stage, many authors recommend against overinterpretation of differences in treatment effect between subgroups, again due to this prior belief in consistency (e.g., Lagakos 2006).”
BackgroundMethodBorghi, L., Nouvenne, A., Prati, B., Allegri, F., Guerra, A., Maggiore, U., & Meschi, T. (2009) · Giornale di Clinica Nefrologica e Dialisi · doi:10.33393/gcnd.2009.1266 · Cited by 1
Variable selection for decision making
Gunter, L. (2009) · Deep Blue (University of Michigan) · Cited by 1
What should we learn from the failure of an activated protein C?
Izawa, J., Uchino, S., & Sanui, M. (2012) · Journal of the Japanese Society of Intensive Care Medicine · doi:10.3918/jsicm.19.586 · Cited by 1
Hall, W. A., & Torres, M. A. (2012) · Breast Diseases A Year Book Quarterly · doi:10.1016/j.breastdis.2012.04.012 · Cited by 1
Low-density lipoprotein cholesterol goals: still not in patients' best interest
Mayer, M. G. (2016) · BMJ Evidence-Based Medicine · doi:10.1136/ebmed-2016-110383 · Cited by 1
New Advancements in Exposure-Response Analysis to Inform Regulatory Decision Making
Zhao, L. Y., Li, H., Marathe, A., Yu, J., Rekić, D., Mehrotra, N., Sinha, V. P., & Wang, Y. (2016) · Springer eBooks · doi:10.1007/978-3-319-39053-6_13 · Cited by 2
Wang, H., Belitskaya‐Lévy, I., Shih, M., & Lü, Y. (2017) · Springer eBooks · doi:10.1007/978-3-319-53877-8_18 · Cited by 1
Tools for Assessment of Cardiovascular Tests and Therapies
Antman, E. M., Califf, R. M., & Kupersmith, J. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3358-5.50007-3 · Cited by 1
Medical Biostatistics: Basic Concepts
Bougioukas, K. I., & Haidich, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-92946-0_2 · Cited by 1
Semi-parametric Bayesian regression for subgroup analysis in clinical trials
Gamalo, M., & Tiwari, R. C. (2019) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2019.1572613 · Cited by 1
“However, because subgroup analysis has a proclivity to detect spurious effects, many reviews [see, inter alia, Pocock et al. (2002), Rothwell (2005), Lagakos (2006)] have been published recommending that appropriate emphasis should always be placed on the primary outcome of the study and to plan…”
BackgroundLatent Supervised Learning for Estimating Treatment Effect Heterogeneity
Wei, S. H., & Kosorok, M. R. (2014) · Collection of Biostatistics Research Archive (COBRA) · Cited by 2
Mehrzad, M., Kang, A. S., Armstrong, A. W., & Eisen, D. B. (2024) · Dermatologic Surgery · doi:10.1097/dss.0000000000004113 · Cited by 1
Wittholz, K., Fetterplace, K., Chapple, L. S., Ridley, E. J., Finnis, M., Presneill, J., Chapman, M., Peake, S., Bellomo, R., Karahalios, A., et al. (2024) · Australian Critical Care · doi:10.1016/j.aucc.2024.09.001 · Cited by 1
New immune modulatory drugs for systemic lupus erythematosus—what can we expect?
Davidson, A. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0301 · Cited by 1
“Finally, trial designs and analyses must be optimally planne”
BackgroundAntiplatelet agents for secondary prevention of stroke
Bernstein, R. A. (2008) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-008-0024-y · Cited by 1
Chains of evidence, mosaics of data: does estrogen ‘cause’ breast cancer? How would we know?
Bluming, A. Z., & Tavris, C. (2012) · Climacteric · doi:10.3109/13697137.2012.678915 · Cited by 2
Problematic Use of Multiple Subgroup Analyses in Assessing the Impact of Aspirin in Prostate Cancer
Lee, M., Wong, H., & Gibbs, P. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.7010 · Cited by 1
Gerinnungsaktive Medikamente zur Sekundärprophylaxe bei pAVK: Bewährte und neue Therapieansätze
Grebe, M. (2006) · Gefässchirurgie · doi:10.1007/s00772-006-0484-x · Cited by 1
“Hierbei muss allerdings betont werden, dass die Daten solcher (nachträglichen) Subgruppenanalysen grundsätzlich nur mit großer Vorsicht interpretiert werden sollten [17].”
BackgroundGiacchetti, S., Gorlia, T., Garufi, C., & Lévi, F. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4763 · Cited by 1
P -Values, Evidence, and Multiplicity Considerations for Controlled Clinical Trials
Huque, M. F., Alosh, M., Dubey, S. D., & Bhore, R. (2010) · Informa Healthcare eBooks · doi:10.3109/9781439822463.153 · Cited by 1
Statistical Issues and Challenges
Regan, M. M. (2009) · Cancer treatment and research · doi:10.1007/978-0-387-75115-3_6 · Cited by 1
“Recently Lagakos [ 12 ], who has been widely referenced as opposed to subgroup analyses, restated the need for cautious interpretation of subgroup analyses writing ‘‘When subgroup analyses are properly conducted, presentation of their results can be informative, especially when the treatments being compared are used i…”
BackgroundHelbekkmo, N. (2009) · NORA - Norwegian Open Research Archives · Cited by 1
Regulatory Issues in the Co-Development of Oncology Drugs and Proteomic Tests: An Overview
Li, D., Hackett, J., Chan, M. M., Pennello, G. A., & Gutman, S. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-169-7_11
Percutaneous treatment of complex lesions and complex patients
Wykrzykowska, J. J. (2011) · RePub (Erasmus University Rotterdam)
Specific Treatments for Acute Ischaemic Stroke
Warlow, C., van Gijn, J., Dennis, M. S., Wardlaw, J. M., Bamford, J., Hankey, G. J., Sandercock, P. A., Rinkel, G. J. E., Langhorne, P., Sudlow, C. L. M., et al. (2008) · Wiley eBooks · doi:10.1002/9780470696361.ch12
Management of Chronic Coronary Artery Disease
Thomas, S., & Boden, W. E. (2012) · Wiley eBooks · doi:10.1002/9781118399378.ch3
Iparraguirre, H. P., & Tajer, C. D. (2006) · Redalyc (Universidad Autónoma del Estado de México)
Survival Analysis with High-Dimensional c\Covariates, with Applications to Cancer Genomics
Zhao, S. D. (2012) · Digital Access to Scholarship at Harvard (DASH) (Harvard University) · Cited by 1
Rosenstein, R. S., & Parra, D. (2009) · Circulation · doi:10.1161/circulationaha.108.829838
Author Index to Volume 29 (2006)
NISCHAN, P. (2006) · International Journal of Rehabilitation Research · doi:10.1097/01.mrr.0000230054.08981.86
Das ABC der medizinischen Statistik – Klinische Studien lesen und verstehen
Labenz, J., & Kunz, C. U. (2011) · Spektrum der Augenheilkunde · doi:10.1007/s00717-011-0041-1
Risk of cancer from blood donated by people with cancer
Chae, Y. K., & Yun, J. H. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61286-0
Risk of cancer from blood donated by people with cancer – Authors' reply
Nyrén, O., Edgren, G., Hjalgrim, H., Reilly, M., & Melbye, M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61287-2
Wan, S. (2010) · doi:10.17077/etd.mrx0c653
“The moderated regression approach, which is based on a general approach to testing statistical interactions, is recommended to address these limitations (Brookes et al. 2004; Lagakos 2006; Pocock et al. 2002; Wang et al. 2007).”
MethodPredicting who will benefit from treatment
Herbison, P. (2009) · Neurourology and Urodynamics · doi:10.1002/nau.20656
How should a clinician interpret results of randomized controlled trials?
Šapoka, V., Kasiulevičius, V., & DIDŽIAPETRIENĖ, J. (2010) · Acta medica Lituanica · doi:10.2478/v10140-010-0004-x
Motivational interviewing in alcohol reduction
Hutcheson, C. (2012) · British Journal of Mental Health Nursing · doi:10.12968/bjmh.2012.1.2.122
“However, the study was a secondary data analysis assessing multiple data associations and thus should be viewed as exploratory and not confirmatory (Lagakos, 2006).”
BackgroundLowe, M., & Hayhow, B. (2006) · Australian Prescriber · doi:10.18773/austprescr.2006.076
Donneyong, M. M. (2013) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/365 · Cited by 1
“According to Lagakos (2003), subgroup analysis, when performed and reported in a responsible manner, has great utility in clinical practice (168).”
BackgroundMethodPrevention Trials: Design and Analysis Considerations
Drye, L. T., & Meinert, C. L. (2011) · Pharmaceutical Medicine · doi:10.1007/bf03256880 · Cited by 1
Hall, W. A., & Torres, M. A. (2012) · Yearbook of Oncology · doi:10.1016/s1040-1741(12)00201-1
Hernández‐Cordero, S., Barquera, S., Rodríguez‐Ramírez, S., Villanueva‐Borbolla, M. Á., de Cossío, T. G., Rivera, J. Á., & Popkin, B. M. (2015) · Journal of Nutrition · doi:10.3945/jn.115.211680
Adjuvant chemotherapy for local relapse breast cancer
Ogden, S. (2014)
Tools for Assessment of Cardiovascular Tests and Therapies
Antman, E. M., Califf, R. M., & Choudhry, N. K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00001-1 · Cited by 1
Issues in Trial Design and Areas Needing Further Research
Abraldeṣ, J. G., Salerno, F., Augustín, S., Ripoll, C., Reiberger, T., Moreau, R., Albillos, A., & García–Tsao, G. (2015) · Springer eBooks · doi:10.1007/978-3-319-23018-4_35
Cardiovascular Clinical Trials: Putting the Evidence into Practice
(2012) · Wiley eBooks · doi:10.1002/9781118399378
Das ABC der medizinischen Statistik: Klinische Studien lesen und verstehen
Labenz, J. (2010) · Der MKG-Chirurg · doi:10.1007/s12285-010-0160-8
Neue Webseite: „Mum hat Brustkrebs“
(2011) · best practice onkologie · doi:10.1007/s11654-011-0303-z
Statistical methods to study heterogeneity of treatment effects
Taft, L. (2015) · IUScholarWorks (Indiana University) · doi:10.7912/c2/2786
Patellofemoral Pain : Unravelling its Course and Treatment
Lankhorst, N. E. (2015) · RePub (Erasmus University Rotterdam)
Designing and Interpreting Clinical Studies in Infectious Diseases
Powers, J. H. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00052-7
Schreiner, A. M. (2014) · STARS (University of Central Florida)
Prognostic factors in prostate cancer biopsies: A population-based cohort study
Sæter, T. (2017) · NORA - Norwegian Open Research Archives · Cited by 1
Should Subgroup Analysis of Randomized Clinical Trials Have a Direct Impact on Clinical Practice
Bradbury, A. R., & Olopade, O. I. (2011)
Fu, H., & Zhou, J. J. (2017) · Model Assisted Statistics and Applications · doi:10.3233/mas-170403
“Much has been written about the dangers of subgroup analyses (Brookes et al., 2004; Lagakos, 2006; Ruberg et al., 2010), and various authors have proposed guidelines for analysis and reporting on subgroups (Roth-well, 2005; Wang et al., 2007).”
Subgroup Analyses and Information from Clinical Trials on Breast Cancer
Yip, W. (2017) · Springer eBooks · doi:10.1007/978-3-319-48848-6_79
Optimizing Imperfect Patient Management Recommendations Post-prostatectomy
Roach, M., & Lazar, A. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.03.014
The Role of Infections in the Etiology of Childhood Acute Lymphoblastic Leukemia
Hwee, J. (2018) · TSpace (University of Toronto)
A non-parametric statistical test of null treatment effect in sub-populations
Taft, L., & Shen, C. (2019) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2019.1636810
“The caveats of existing subgroup analysis approaches have been discussed in multiple publications (Lagakos 2006; Rothwell 2005; Wang et al. 2007).”
Background‘COre SUBgroup SETs (COSUBSET)’ initiative is needed
Sbidian, É., & Cleach, L. L. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18795
Differential effect of ticagrelor on irreversible harms in diabetes
Chi, G., & Marszalek, J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30486-4
Estimation and clustering for partially heterogeneous single index model
Wang, F., Lu, L., Liu, L., & Wang, K. (2020) · Statistical Papers · doi:10.1007/s00362-020-01203-2
“Although subgroup analysis is commonly used for grouping heterogeneous effects, it lacks a rigorous statistical framework and is easy to generate misleading results (Kravitz et al. 2004; Rothwell 2005; Lagakos 2006).”
MethodReply to “Impact of COVID-19 on the mental health of radiologists”
Demirjian, N. L., Fields, B. K. K., Cen, S., Lei, X., & Gholamrezanezhad, A. (2021) · Clinical Imaging · doi:10.1016/j.clinimag.2021.03.025
Epidemiology, Cure, Treatment Trials and Screening
Tobias, J. S., & Hochhauser, D. (2009) · Wiley eBooks · doi:10.1002/9781444306361.ch2
Rosenkranz, G. (2019) · Wiley eBooks · doi:10.1002/9781119536734.ref
Glaser, R., Glick, H. A., Herrmann, H. C., & Kimmel, S. E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.019
Keyword index to Volume 29 (2006)
(2006) · International Journal of Rehabilitation Research · doi:10.1097/01.mrr.0000230055.91054.62
Beloka, S., van de Borne, P., & Naeije, R. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31819af6ad
Re: Pheochromocytoma penetrance varies by RET mutation in MEN 2A
Quayle, F. J., Fialkowski, E., Benveniste, R. J., & Moley, J. F. (2008) · Surgery · doi:10.1016/j.surg.2008.03.004
MacFarlane, L. A., Collins, J. E., Jones, M. H., & Katz, J. N. (2019) · The American Journal of Sports Medicine · doi:10.1177/0363546519852623
Subpopulation Treatment Effect Pattern Plot (STEPP) Methods with R and Stata
Venturini, S., Bonetti, M., Lazar, A., Cole, B. F., Wang, V., Gelber, R. D., & Yip, W. (2022) · Journal of Data Science · doi:10.6339/22-jds1060
Heterogeneity Exploration for Multi-Response Regression
Wu, J., Gao, W., Dong, R., & Zheng, Z. (2023) · Communications in Mathematics and Statistics · doi:10.1007/s40304-023-00342-w
“Among them, some meth-ods focus on fixed covariates which do not vary with subgroups [6, 11].”
Caution against overoptimistic findings
Kouzan, S., & Chevret, S. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.795
Bayesian Shrinkage Estimation of Credible Subgroups for Count Data with Excess Zeros
Ngo, D., Quartey, D., Schnell, P., Baumgartner, R., Mt‐Isa, S., & Feng, D. (2024) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2024.2388520
“The drawback to this approach is that there are too many potential characteristics that can influence treatment effect, and this leads to low power and false positive findings due to multiple testings (Berry 1990; Cui et al. 2002; Lagakos 2006).”
Wang, F., Chen, Y., Li, J., Zhou, Q., & Zhang, R. (2025) · Journal of the Korean Statistical Society · doi:10.1007/s42952-025-00308-4
“…et al. (2010) elucidated the importance of efficient sub-group identification for statistical medical research problems; Brookes et al. (2004) and Lagakos et al. (2006) analyzed the advantages and challenges of subgroup analysis; Varadhan et al. (2013) demonstrated that in-depth research on…”
Avenell, A., Robertson, C., Boachie, B., Stewart, F., Archibald, D., Douglas, F., Hoddinott, P., & van Teijlingen, E. (2016) · Bournemouth University Research Online (Bournemouth University) · Cited by 1
Toepassingen van Machinaal Leren in de Pneumologie: Hulpmiddelen voor Klinische Besluitvorming
Verstraete, K. (2024) · Lirias
Gil Sierra, M. D. (2023) · idUS (Universidad de Sevilla)
Remala, S., Liang, L., Shah, A. M., & Buckley, L. F. (2026) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.125.005535
The challenging combination of a high cardiac output and pulmonary arterial hypertension
Naeije, R., & Savale, L. (2026) · European Respiratory Journal · doi:10.1183/13993003.02698-2025
Mei, J., Zhang, K., Zhang, Y., Li, Z., Ge, N., Han⊗, X., Zhong, S.-X., Zhang, X.-P., Wu, P.-P., Lv, W., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.102004
“29,30 Current international guidelines, including those from the EASL and the AASLD, recommend IO-chemo based on biomarkers such as deficient mismatch repair/microsatellite instability–high, high tumor mutational burden, and high PD-L1 expression.”
Valid Data‐Driven Subgroup Selection With Uniform Guarantees in Clinical Trials
Müller, M., Bornkamp, B., Bretz, F., Cannings, T. I., Liu, W., Reeve, H. W. J., Samworth, R. J., Sfikas, N., Wan, F., & Sechidis, K. (2026) · Statistics in Medicine · doi:10.1002/sim.70745
“Inparticular,inresponsetothedangersofposthoc selection of subgroups, common guidance on subgroup analysis includes the prespecification of a small number of biologically plausible subsets based on domain knowledge and correcting any reported results for multiplicity [4, 8, 17, 18].”
Clinical Trials in Stone Disease
Borghi, L., Maggiore, U., Nouvenne, A., & Meschi, T. (2010) · Springer eBooks · doi:10.1007/978-1-84800-362-0_34
Metadata
- Authors
- Lagakos, S. W.
- Affiliations
- Harvard University (US)
- Corresponding author
- Lagakos, Stephen W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-04-20
- Volume
- 354
- Issue
- 16
- Pages
- 1667-1669
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085477178
- Semantic Scholar
- d03b954bb3525ed19f989e831c39645293c3c984
- Cited by
- 504
- References
- 7
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 23 · 2023: 13 · 2022: 14 · 2021: 13 · 2020: 21 · 2019: 34 · 2018: 21 · 2017: 21 · 2016: 23 · 2015: 29 · 2014: 21 · 2013: 26 · 2012: 29
- FWCI
- 40.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Physical Sciences › Mathematics › Statistics and Probability › Advanced Causal Inference Techniques
- Keywords
- subgroup analysis, subgroup heterogeneity, overinterpretation, reporting bias, treatment effect heterogeneity, randomized controlled trials, primary endpoint
- MeSH terms
- Data Interpretation, Statistical, False Positive Reactions, Probability, Statistics as Topic, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.